Abstract: A monoclonal antibody against human (a69) and mouse clones Triggering Receptor and (Clones Expressed in Myeloid TREM) cells-like transcript-1 or TLT-1 is provided. This antibody also identifies TLT-1 on platelets by flow cytometry, in western blots, by immunofluorescence, ELISA and immunoprecipitation giving it immediate use as a diagnostic tool for research and blood marker and/or treatment for diseases such as disseminated intravascular coagulation. The Antibody can also be used as intervention for any diseases that has or may have a TLT-1 component such as Disseminated Intravascular Coagulation (DIC), Cardiovascular disease (CVD) and cancers and should overcome the problem of blocking platelet function that leads to a bleeding diathesis.

Abstract: The present invention relates to methods and compositions for modulating platelet activity, and methods and compositions for treating a disease or disorder associated with platelet activity in a subject, comprising administering a single chain anti-TREM-like transcript-1 (TLT-1) antibody or a functional fragment or variant thereof in an amount effective to modulate platelet activity.

Abstract: The invention provides isolated nucleic acids molecules, designated TLT-1 nucleic acid molecules, which encode novel inhibitory receptors expressed on platelets. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TLT-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TLT-1 gene has been introduced or disrupted. The invention still further provides isolated TLT-1 proteins, fusion proteins, antigenic peptides and anti-TLT-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.